# Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

> **NCT00323856** · PHASE4 · COMPLETED · sponsor: **Grifols Biologicals, LLC** · enrollment: 51 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** Alphanate SD/HT

## Key facts

- **NCT ID:** NCT00323856
- **Lead sponsor:** Grifols Biologicals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04-08
- **Primary completion:** 2018-12-11
- **Final completion:** 2018-12-14
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323856, "Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00323856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*